CORRECTION article

Front. Pharmacol., 17 September 2025

Sec. Integrative and Regenerative Pharmacology

Volume 16 - 2025 | https://doi.org/10.3389/fphar.2025.1597755

Correction: Resveratrol and Angiogenin-2 combined with PEGDA/TCS hydrogel for the targeted therapy of hypoxic bone defects via activation of the autophagy pathway

  • DF

    Dehui Fan 1†

  • HL

    Hengping Liu 2†

  • ZZ

    Zhenning Zhang 1

  • MS

    Meiyi Su 1

  • ZY

    Zhixian Yuan 1

  • YL

    Ying Lin 1

  • SY

    Shuquan Yang 1

  • WL

    Wenqiang Li 3*

  • XZ

    Xintao Zhang 4*

  • 1. The Fifth Clinical College of Guangzhou University of Chinese Medicine Guangzhou, Guangdong Second Traditional Chinese Medicine Hospital, Guangzhou, China

  • 2. Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing, China

  • 3. Engineering Technology Research Center for Sports Assistive Devices of Guangdong, Guangzhou Sport University, Guangzhou, China

  • 4. Department of Sports Medicine and Rehabilitation, National and Local Joint Engineering, Research Center of Orthopaedic Biomaterials, Peking University Shenzhen Hospital, Shenzhen, China

In the published article, there was an error in Figures 3B, 4A,B as published. Images from different groups were stored in the same folder during image shooting, resulting in the misuse of images. The corrected Figures 3B, 4A,B and their captions appear below.

FIGURE 3

FIGURE 4

In the published article, there was an error in Figures 7A, 8 as published. The H&E, Masson, OCN and CD31 staining images of the animal tissue sections in Figures 7, 8 overlap with those used in our previous published study. This occurred because the animal experiments for both research projects were conducted concurrently, leading to inadvertent misplacement of data files. The corrected Figures 7A, 8 and their captions appear below.

FIGURE 7

FIGURE 8

The original article has been updated.

Statements

Generative AI statement

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

resveratrol, ANG2, autophagy, hypoxia condition, vascularization, bone defect

Citation

Fan D, Liu H, Zhang Z, Su M, Yuan Z, Lin Y, Yang S, Li W and Zhang X (2025) Correction: Resveratrol and Angiogenin-2 combined with PEGDA/TCS hydrogel for the targeted therapy of hypoxic bone defects via activation of the autophagy pathway. Front. Pharmacol. 16:1597755. doi: 10.3389/fphar.2025.1597755

Received

21 March 2025

Accepted

25 June 2025

Published

17 September 2025

Volume

16 - 2025

Edited and reviewed by

Bernd Rosenkranz, Fundisa African Academy of Medicines Development, South Africa

Updates

Copyright

*Correspondence: Wenqiang Li, , ; Xintao Zhang,

† These authors have contributed equally to this work

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics